MarketPulse

FDA feedback

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

uniQure Stock Plunges 49% After FDA Gene Therapy Setback; Class Action Launched

Pomerantz Law Firm filed class action against $QURE after 49% stock decline following FDA concerns over gene therapy study data adequacy.
SMRQUREAMCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

uniQure Stock Plunges 49% on FDA Gene Therapy Setback; Class Action Lawsuit Filed

$QURE plummeted 49% after FDA feedback on AMT-130 gene therapy. Pomerantz Law Firm filed class action lawsuit; investor deadline April 13, 2026.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Gene Therapy Setback Triggers Class Action as uniQure Stock Plummets 49%

uniQure shares collapsed 49% after FDA signaled Phase I/II data insufficient for AMT-130 approval, prompting investors to file class action lawsuit.
QUREclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Names Veteran Pharma Executive Huston as CFO

Artiva Biotherapeutics appoints veteran pharma executive Thad Huston as CFO with 30+ years experience, ahead of key FDA feedback and clinical data milestones.
ARTVrestricted stock unitsautoimmune diseases